BioTuesdays

Cantargia AB (Nasdaq Stockholm: CANTA) has announced the appointment of Wolfram Dempke, MD, PhD, MBA as chief medical officer (CMO), effective immediately. Dr. Morten Lind Jensen, who has served as CMO since March 2025, will leave Cantargia to pursue other opportunities. https://lnkd.in/gagQw9q6

Perspective Therapeutics (NYSE American: CATX) has announced that the first patient has been dosed in the second cohort of a Phase 1/2a dose-finding trial to determine the safety and preliminary anti-tumor activity of PSV359 in patients with solid tumors that express fibroblast activation protein alpha (FAP-a). https://lnkd.in/gv2qej5Q

Profusa (NASDAQ: PFSA) has announced that Yann Gouëffic, MD, PhD, professor of vascular surgery in the Vascular Center at Groupe Hospitalier Paris Saint Joseph, Paris, France will adopt the company’s Lumee oxygen monitoring technology in his practice and in clinical studies, advancing application of Lumee for home monitoring. https://lnkd.in/ea3dxKQH

Sera Prognostics (NASDAQ: SERA) has announced the appointment of Tiffany Inglis, MD, FACOG, as chief medical officer (CMO). https://lnkd.in/egJMaUNr

Larimar Therapeutics Inc. (NASDAQ: LRMR) has announced positive 25 mg and 50 mg data from the ongoing long-term open label (OL) study evaluating daily subcutaneous injections of nomlabofusp self-administered or administered by a caregiver in participants with Friedreich’s ataxia (FA). https://lnkd.in/gkQS3hBJ

Cue Biopharma (NASDAQ: CUE) has announced that Usman Azam, MD has been appointed president and CEO of Cue Biopharma, effective today. Daniel Passeri will transition from his current role as CEO to one of strategic advisor. https://lnkd.in/g4DKWutD

🌟 Feature Article 🌟 In our latest #BioTuesdays feature, Cell One PARTNERS founder and CEO George Goldberger shares how the firm is guiding cell and gene therapy innovators from breakthrough science to market impact. With deep expertise, global networks, and real-world operational experience, Cell One Partners helps bridge the gap between the lab bench and the patient bedside, accelerating the next generation of transformative therapies. 📖 Read the full article: https://lnkd.in/evZCfkG4 #CellTherapy #GeneTherapy #HealthcareInnovation #LifeSciences #Biotech Kilmer Lucas Inc.

Anebulo Pharmaceuticals (NASDAQ: ANEB) has announced first patients dosed in its Phase 1 single ascending dose (SAD) study intravenous selonabant—under development for acute cannabis-induced (ACI) toxicity—in healthy young adults. https://lnkd.in/gK34Qwjt

ME Therapeutics (CSE: METX; FSE: Q9T) has announced that the United States Patent Office (USPTO) has granted its subsidiary, ME Therapeutics, a patent for its lead G-CSF antibody candidate. https://lnkd.in/g9n4THh7

Nexalin Technology (Nasdaq: NXL; NXLIW) has announced that the United States Patent and Trademark Office (USPTO) has issued a design patent providing 15 years of protection for the company’s next-generation HALO Clarity neuromodulation device. https://lnkd.in/gk9DzUFJ